Back to Search
Start Over
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Source :
- Journal of the American Academy of Dermatology. 78(6)
- Publication Year :
- 2017
- Subjects :
- Adult
Male
Ruxolitinib
medicine.medical_specialty
Time Factors
Administration, Topical
Vitiligo
Dermatology
Risk Assessment
Severity of Illness Index
Drug Administration Schedule
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Nitriles
Medicine
Humans
Prospective Studies
Janus kinase inhibitor
Janus Kinases
Dose-Response Relationship, Drug
business.industry
Extension study
Follow up studies
Ultraviolet b
Middle Aged
medicine.disease
Combined Modality Therapy
Narrow band
Pyrimidines
Treatment Outcome
030220 oncology & carcinogenesis
Pyrazoles
Female
Ultraviolet Therapy
Open label
business
medicine.drug
Follow-Up Studies
Subjects
Details
- ISSN :
- 10976787
- Volume :
- 78
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Journal of the American Academy of Dermatology
- Accession number :
- edsair.doi.dedup.....d7ad0ef5b2b23f245d9e4bfe1420684a